当前位置：
X-MOL 学术
›
Liver Int.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
COVID-19 and the liver: A 2021 update
Liver International ( IF 6.0 ) Pub Date : 2021-06-21 , DOI: 10.1111/liv.14984 Catherine W Spearman 1 , Alessio Aghemo 2, 3 , Luca Valenti 4, 5 , Mark W Sonderup 1
Liver International ( IF 6.0 ) Pub Date : 2021-06-21 , DOI: 10.1111/liv.14984 Catherine W Spearman 1 , Alessio Aghemo 2, 3 , Luca Valenti 4, 5 , Mark W Sonderup 1
Affiliation
In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China and has since resulted in a global pandemic in excess of 165 million reported infections and 3.4 million attributable deaths. COVID-19 is primarily a respiratory illness, which may be complicated by pneumonia and acute respiratory distress syndrome. SARS-CoV-2 is also responsible for numerous extrapulmonary manifestations involving the haematologic, cardiovascular, renal, gastrointestinal and hepatobiliary, endocrinologic, neurologic, ophthalmologic and dermatologic systems. This review will discuss the pathophysiology of COVID-19; focusing on the mechanisms and outcomes of liver injury associated with COVID-19; its impact on chronic liver disease (CLD); management of CLD during the COVID-19 pandemic and the long-term impact of COVID-19 on CLD.
更新日期：2021-08-17
京公网安备 11010802027423号